Updates in Psoriasis Treatment: New Data From Vienna
Plaque psoriasis is a debilitating, noncurable autoimmune disorder, having a significant impact on quality of life, associated with depression, anxiety, social isolation, unemployment, and suicide. Various therapies, such as topical formulations and phototherapy, are currently available. The latest breakthroughs in understanding the immunopathology underlying plaque psoriasis include the identification of interleukins (IL-17, IL-22, and IL-23), which drive the chronic inflammatory nature of the disease. Multiple types of therapies in several drug classes are available and more are in the pipeline. In this Rapid Response activity, the latest evidence from the 2016 European Academy of Dermatology and Venereology Congress meeting on the efficacy and safety of new and emerging therapies for plaque psoriasis will be examined.
Educational Partner: Vindico Medical Education
Medium: Online Presentation
Commerical Support: This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.
Learning Objectives and Target Audience
Upon completion of this activity, participants will be able to:
- Examine new evidence regarding treatment selection for plaque psoriasis based on disease severity and how the mechanisms of action of new and emerging therapies target the immunological pathways of the disease;
- Analyze the latest efficacy data of new and emerging therapies for plaque psoriasis, including small-molecule inhibitors and immunotherapy;
- Evaluate the latest safety data pertaining to the use of immunotherapy in the treatment of plaque psoriasis to assist in the development of strategies to prevent, recognize, and effectively manage potential adverse effects.
The intended audience for the activity is dermatology physicians, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with psoriasis.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.